A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
Otsuka Holdings’half-year pharma sales grew 7.6% year on year thanks to buoyant revenues from four global brands including the antipsychotic agents Abilify Maintena (aripiprazole) and Rexulti/Rxulti (brexpiprazole). In January-June, the company generated sales of 471,773 million yen in its pharmaceutical…
To read the full story
Related Article
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
May 1, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
May 15, 2023
- Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
February 15, 2023
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
- Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
May 16, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
August 10, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
BUSINESS
- Japan Ethical Drug Sales Up 3.3% in November: Crecon
January 14, 2025
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Amitiza Most Heavily Pitched Medicine for Hospital Doctors in November: Intage
January 10, 2025
- FDA Accepts Re-Submission of Izervay to Buttress Label
January 10, 2025
- Keytruda Grabs Best-Seller Crown for 15th Month in December: Encise
January 10, 2025
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…